Pivotal role of an aliphatic side chain in the development of an HDM2 inhibitor

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 572-575

  Ma, Yao ^a   Lahue, Brian R ^a   Gibeau, Craig R ^a   Shipps, Gerald W ^a   Bogen, Stéphane L ^a   Wang, Yaolin ^a   Guo, Zhuyan ^a   Guzi, Timothy J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HDM2; MDM2; p53; protein protein interaction; small molecule inhibitor; substituted piperidine

Indexed keywords

ALIPHATIC COMPOUND; LIGASE INHIBITOR; PIPERIDINE DERIVATIVE; PROTEIN MDM2; UBIQUITIN PROTEIN LIGASE HDM2 INHIBITOR; UNCLASSIFIED DRUG;

AMIDATION; ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 84900389550     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500019s     Document Type: Article

References (23)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division Cell 1997, 88, 323-331
2. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53 Nat. Rev. Cancer 2002, 2, 594-604
3. Oren, M. Decision making by p53: life, death and cancer Cell Death Differ. 2003, 10, 431-442
4. Fridman, J. S.; Lowe, S. W. Control of apoptosis by p53 Oncogene 2003, 22, 9030-9040
5. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug Discovery 2008, 7, 979-987
6. Chen, J.; Wu, X.; Lin, J.; Levine, A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein Mol. Cell. Biol. 1996, 16, 2445-2452
7. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 1992, 69, 1237-1245
8. Momand, J.; Wu, H. H.; Dasgupta, G. MDM2: master regulator of the p53 tumor suppressor protein Gene 2000, 242, 15-29
9. Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53 Nature 1993, 362, 857-860
10. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database Nucleic Acids Res. 1998, 26, 3453-3459
11. Polsky, D.; Bastian, B. C.; Hazan, C.; Melzer, K.; Pack, J.; Houghton, A.; Busam, K.; Cordon-Cardo, C.; Osam, I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma Cancer Res. 2001, 61, 7642-7646
12. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3, 102-109
13. Bottger, A.; Bottger, V.; Sparks, A.; Liu, W.-L.; Howard, S. F.; Lane, D. P. Design of a synthetic MDM2-binding mini protein that activates the p53 response in vivo Curr. Biol. 1997, 7, 860-869
14. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
15. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303, 844-848
16. Hu, C.-Q.; Hu, Y.-Z. Small molecule inhibitors of the p53-MDM2 Curr. Med. Chem. 2008, 15, 1720-1730
17. Patel, S.; Player, M. R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer Expert Opin. Invest. Drugs 2008, 17, 1865-1882
18. Ma, Y.; Lahue, B.; Shipps, G.; Brookes, J.; Wang, Y. Substituted piperidines as HDM2 inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 1026-1030
19. Ma, Y.; Lahue, B.; Shipps, G.; Wang, Y.; Bogen, S.; Voss, M.; Nair, L.; Tian, Y.; Doll, R.; Guo, Z.; Strickland, C.; Zhang, R.; McCoy, M.; Pan, W.; Siegel, E.; Gibeau, C. Preparation of substituted piperidines that increase p53 activity and the uses thereof. U.S. Pat. Appl. Publ. US2008004287, 2008.
20. Brubaker, A.; Colley, M. Synthesis and pharmacological evaluation of some 6-substituted 7-methyl-1,4-dioxa-7-azaspiro[4.5]decanes as potential dopamine agonists J. Med. Chem. 1986, 29, 1528
21. Cvetovich, R. J.; Chung, J. Y. L.; Kress, M. H.; Amato, J. S.; Matty, L.; Weingarten, M. D.; Tsay, F.-R.; Li, Z.; Zhou, G. An efficient synthesis of a dual PPAR α/γ agonist and the formation of a sterically congested α-aryloxyisobutyric acid via a Bargellini reaction J. Org. Chem. 2005, 70, 8560-8563
22. Rychnovsky, S. D.; Beauchamp, T.; Vaidyanathan, R.; Kwan, T. Synthesis of chiral nitroxides and an unusual racemization reaction J. Org. Chem. 1998, 63, 6363-6374
23. Zhang, R.; Mayhood, T.; Lipari, P.; Wang, Y.; Durkin, J.; Syto, R.; Gesell, J.; McNemar, C.; Windsor, W. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction Anal. Biochem. 2004, 331, 138-146